Newswise — Oct. 01, 2020 – Today, the ATS Research Program announced three research grant opportunities with support from 4DMedical, a global medical technology company with a focus on lung health. With a total grant support of $150,000, each of the three $50,000 grants will fund research in asthma, chronic obstructive pulmonary disorder or COPD, and idiopathic pulmonary fibrosis or IPF.
All three grants, which are for one year, will use 4DMedical’s x-ray velocimetry lung ventilation analysis software.
"4DMedical aims to contribute to the ATS mission to help the world breathe by revolutionizing respiratory imaging and ventilation analysis. Our vision is to provide access to advanced technology providing patients and their doctors with better information and thereby promoting better outcomes for a wider range of patients with chronic and progressive lung diseases," said Professor Andreas Fouras, PhD, founder, CEO and CTO, 4DMedical.
“These three grants are a welcome addition to the ATS Research Program,” said MeiLan Han, MD, MS. “Advanced technology in respiratory imaging and ventilation analysis has the potential to advance our understanding of lung diseases and guide decisions in patient care. We’re grateful the 4DMedical for providing these opportunities for further research.”
The application process opens today, Oct. 1, 2020.
Interested applicants may hear more about this grant opportunity here.
Share Via Tweet
@atscommunity #research program and @4dmedical announce grant opportunities for #research in #asthma, #COPD and #IPF.
About the ATS Research Program The American Thoracic Society and its Research Program are improving respiratory health worldwide by supporting young investigators in pulmonary, critical care, and sleep medicine. The ATS Research Program, established in 2004, bolsters new investigators as they strive to launch independent research careers dedicated to innovation in patient care.
Since 2004, the Research Program has awarded $19.3 million in research grants to 263 investigators who have gone on to secure more than $330 million in federal funding. That's a return on investment of $17 per dollar awarded.
Based in Melbourne, Australia and Los Angeles, California, USA, 4DMedical (formerly 4Dx) was founded in 2013 and is listed on the Australian Securities Exchange (ASX:4DX).
4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.
The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.
Respiratory diagnosis is a $30 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.